RAXAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RAXAR (RAXAR).
RAXAR (revumenib) is a selective inhibitor of the menin-KMT2A protein-protein interaction. By binding to menin, it blocks the interaction with KMT2A (MLL1), thereby disrupting the transcription of oncogenic genes such as HOXA9 and MEIS1, leading to differentiation and apoptosis of leukemic cells.
| Metabolism | Primarily metabolized by CYP3A4. Minor contributions from CYP2C9, CYP2D6, and UGT1A1. The drug is a substrate of P-glycoprotein (P-gp). |
| Excretion | Primarily hepatic metabolism; renal excretion of unchanged drug <5%; biliary/fecal elimination as metabolites accounts for >90% of total clearance. |
| Half-life | Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 25 hours). |
| Protein binding | 99% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.2-0.4 L/kg, indicating distribution primarily within the extracellular fluid and limited tissue penetration. |
| Bioavailability | Oral: 60-70% (first-pass metabolism reduces absolute bioavailability). |
| Onset of Action | Oral: 1-2 hours; Intravenous: 15-30 minutes. |
| Duration of Action | 12-24 hours; sustained effects with once-daily dosing due to long half-life. |
| Molecular Weight | 450.5 |
Subcutaneous injection: 200 mg once daily, irrespective of timing of meals.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). For severe renal impairment (eGFR <30 mL/min) or end-stage renal disease, no data available; use with caution. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). For moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment, no data available; use with caution. |
| Pediatric use | Not approved for use in pediatric patients (age <18 years). Safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended for elderly patients (≥65 years); dosing based on renal function as per adult guidelines. |
| 1st trimester | Avoid during first trimester unless benefit outweighs risk; may cause fetal harm. |
| 2nd trimester | Use only if clearly needed; potential fetal toxicity. |
| 3rd trimester | Avoid in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. |
Clinical note
Comprehensive clinical and safety monograph for RAXAR (RAXAR).
| Placental transfer | Crosses placenta in animal studies; human data limited but expected to transfer. |
| Breastfeeding | No data on excretion in human milk; based on molecular weight and properties, likely present. Use caution, especially with neonates. |
| Lactation Rating |
■ FDA Black Box Warning
Differentiation syndrome, which can be fatal, has been reported in patients treated with RAXAR. Patients should be monitored for symptoms such as fever, dyspnea, pulmonary infiltrates, pleural effusions, hypotension, and renal impairment. At the first sign of symptoms, corticosteroids and hemodynamic support should be initiated.
| Serious Effects |
Hypersensitivity to RAXARSevere hepatic impairmentThird trimester pregnancy
| Precautions | Differentiation syndrome: Manage with corticosteroids and hemodynamic support., QTc interval prolongation: Monitor electrolytes and ECG at baseline and during treatment., Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception., Hematologic toxicity: Monitor blood counts regularly., Hepatotoxicity: Monitor liver function tests. |
| Food/Dietary | RAXAR absorption is not significantly affected by food, but taking it with a high-fat meal may delay absorption; it is best taken on an empty stomach 30 minutes before meals. Avoid alcohol as it can exacerbate GERD symptoms. No specific food interactions; however, PPIs may reduce absorption of vitamin B12 with long-term use, so consider supplementation in elderly or malnourished patients. |
Loading safety data…
| L3 |
| Teratogenic Risk | RAXAR is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, particularly neural tube defects and cardiovascular anomalies based on animal studies and postmarketing data. Second trimester: Continued risk of fetal toxicity including oligohydramnios and renal impairment. Third trimester: Risk of neonatal complications such as respiratory distress and hypotension due to placental transfer. |
| Fetal Monitoring | Monitor hepatic function, renal function, and complete blood count monthly during therapy. For potential fetal exposure, perform serial fetal ultrasound assessments every 4 weeks to detect anomalies. If pregnancy occurs, discontinue RAXAR immediately and refer to maternal-fetal medicine specialist. |
| Fertility Effects | RAXAR may impair female fertility by disrupting ovulatory cycles as observed in animal studies. In males, it can reduce sperm count and motility, with effects reversible upon discontinuation. Contraception is recommended during treatment and for 3 months after last dose. |
| Clinical Pearls | RAXAR (rabeprazole) is a proton pump inhibitor (PPI) used for GERD, erosive esophagitis, and gastric ulcer. Max effect occurs after 4 days. Avoid concurrent use with clopidogrel (reduces antiplatelet effect). For IV form, reconstitute with 0.9% NaCl and use within 24 hours. Monitor magnesium levels with prolonged use. Best taken 30 minutes before breakfast for nighttime symptom control. |
| Patient Advice | Take exactly as prescribed, usually once daily before the first meal of the day. · Swallow tablets whole; do not crush or chew. · If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; do not double doses. · Avoid alcohol and spicy foods which may worsen symptoms. · Report any persistent diarrhea, abdominal pain, or signs of hypomagnesemia (muscle cramps, irregular heartbeat). · Do not use this medication for immediate heartburn relief; onset of action is delayed. |